Kaskela Law Challenges Select Medical Buyout Price as Inadequate

Event summary

  • Kaskela Law is investigating the fairness of Select Medical's $16.50 per share buyout price, announced on March 2, 2026.
  • The acquisition will delist Select Medical's shares from the NYSE following the transaction's closure.
  • At least one analyst had a higher price target of $19.00 per share at the time of the buyout announcement.

The big picture

Kaskela Law's investigation highlights the ongoing tension between buyout prices and market valuations, particularly in the healthcare sector. The firm's focus on merger and acquisition litigation underscores the increasing scrutiny of such transactions by shareholders. The outcome of this investigation could set a precedent for future buyouts in the industry.

What we're watching

Fairness Assessment
How Kaskela Law's investigation will impact the perceived fairness of the $16.50 per share buyout price.
Shareholder Response
Whether Select Medical shareholders will challenge the buyout price, potentially leading to legal action.
Analyst Reactions
The pace at which other analysts adjust their price targets in light of the buyout and investigation.

Related topics

Acquisition